胸部磁共振成像与计算机断层扫描联合模态评估局部晚期非小细胞肺癌同步放化疗后的肿瘤反应
本研究纳入153例接受同步放化疗的局部晚期非小细胞肺癌患者,于化疗后2个月用RECIST标准(CT)和改良标准(胸部MRI联合CT)评估肿瘤反应,并以PFS≥18个月为完全缓解的替代终点验证准确性。改良标准较RECIST标准显著提高完全缓解检出率(35.9% vs 5.2%),敏感性71.2% vs 9.1%,特异性90.8% vs 97.7%;改良标准评估的完全缓解是PFS和总生存的独立预后因素。
要点
- 改良标准(MRI联合CT)评估完全缓解率35.9%,RECIST标准仅5.2%。
- 以PFS≥18个月为替代终点,改良标准敏感性71.2%、特异性90.8%,RECIST分别为9.1%、97.7%。
- 改良标准评估的完全缓解是PFS(HR 0.182)和总生存(HR 0.134)的独立预后因素。
核心结论
- 联合多参数MRI和CT成像可提高局部晚期非小细胞肺癌根治性同步放化疗后肿瘤反应评估的准确性,有助于临床实践中的风险分层和生存预测。
研究设计与样本
- 研究分析了153例接受同步放化疗并连续进行胸部MRI和CT随访的局部晚期非小细胞肺癌患者。
- 于同步放化疗完成后2个月评估肿瘤反应,比较RECIST标准(CT成像)与改良标准(胸部MRI联合CT成像),并在随访影像上验证。
- 胸部MRI扫描分析包括T1C、T2fs、DWI成像及表观扩散系数值。
- 以无进展生存期≥18个月作为完全缓解的替代终点,分析肿瘤反应评估的准确性。
主要发现
- RECIST标准判定8例(5.2%)患者为完全缓解,改良标准判定55例(35.9%)为完全缓解(CT+MRI)。
- 以PFS≥18个月为完全缓解替代终点,改良标准的敏感性和特异性分别为71.2%和90.8%(AUC=0.810,95%CI 0.735-0.885)。
- RECIST标准的敏感性和特异性分别为9.1%和97.7%(AUC=0.534,95%CI 0.441-0.627)。
- 完全缓解(CT+MRI)患者的中位PFS为58.4个月,非完全缓解患者为9.7个月(P<0.001)。
- 多因素分析显示,改良标准评估的肿瘤反应(完全缓解vs非完全缓解)是PFS(HR 0.182,95%CI 0.088-0.373,P<0.001)和总生存(HR 0.134,95%CI 0.044-0.410,P<0.001)的独立因素。
关键数值与推荐
- 改良标准完全缓解定义为联合胸部MRI和CT成像评估的完全缓解。
- RECIST标准完全缓解定义为CT成像评估的完全缓解。
- 以PFS≥18个月作为完全缓解的替代终点。
临床怎么用
- 联合多参数MRI和CT成像可提高局部晚期非小细胞肺癌同步放化疗后肿瘤反应评估的准确性,有助于风险分层和生存预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to explore the role of a modified criteria for assessing tumor response to concurrent chemoradiotherapy (CCRT) in locally advanced non-small cell lung cancer (LA-NSCLC), using the combined modalities of anatomical and functional MRI and CT. MATERIALS AND METHODS: One hundred and fifty-three patients with LA-NSCLC who underwent CCRT with continuous chest MRI and CT follow-up were analyzed. The tumor response to CCRT was evaluated two months after the completion of CCRT. The RECIST criteria (CT imaging) and modified criteria (combined chest MRI and CT imaging) were compared and validated on follow-up imaging. The chest MRI scan analysis included T1C, T2fs, DWI imaging and the apparent diffusion coefficient values. Progression free survival (PFS) ≥ 18 months was used as a surrogate endpoint of complete response to analyze the accuracy of tumor response assessment. RESULTS: Eight (5.2%) patients were considered to have complete response (CR) by the RECIST criteria while fifty-five (35.9%) were considered to have CR (CT + MRI) by the modified criteria. Using PFS ≥ 18 months as a surrogate for CR, the sensitivity and specificity of the modified criteria were 71.2% and 90.8% (AUC = 0.810, 95%CI 0.735-0.885), but were 9.1% and 97.7%, respectively, for the RECIST criteria (AUC = 0.534, 95%CI 0.441-0.627). The median PFS was 58.4 months for patients with CR (CT + MRI) and 9.7 months for those with non-CR (P < 0.001). Multivariate analysis showed that the tumor response evaluated by the modified criteria [CR (CT + MRI) vs. non-CR] was an independent factor for both PFS (HR 0.182, 95%CI 0.088-0.373, P < 0.001) and overall survival (HR 0.134, 95%CI 0.044-0.410, P < 0.001). CONCLUSIONS: Combined multi-parameter MRI and CT imaging could improve the accuracy of tumor response assessment in LA-NSCLC patients after definitive CCRT, therefore contributed to the risk stratification and survival prediction for clinical practice.
引用
- Wang D, Qiu B, He H, et al. Tumor response evaluation by combined modalities of chest magnetic resonance imaging and computed tomography in locally advanced non-small cell lung cancer after concurrent chemoradiotherapy. Radiother Oncol. 2022. PMID: 35131342. doi:10.1016/j.radonc.2022.01.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。